BR112013005432A2 - tratamento de doenças - Google Patents
tratamento de doençasInfo
- Publication number
- BR112013005432A2 BR112013005432A2 BR112013005432A BR112013005432A BR112013005432A2 BR 112013005432 A2 BR112013005432 A2 BR 112013005432A2 BR 112013005432 A BR112013005432 A BR 112013005432A BR 112013005432 A BR112013005432 A BR 112013005432A BR 112013005432 A2 BR112013005432 A2 BR 112013005432A2
- Authority
- BR
- Brazil
- Prior art keywords
- diketopiperazine
- animal
- prodrug
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 abstract 9
- 229940002612 prodrug Drugs 0.000 abstract 3
- 239000000651 prodrug Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 210000004292 cytoskeleton Anatomy 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
tratamento de doenças. a presente invenção refere-se a um método de inibição da impermeabilidade vascular em um animal com necessidade do mesmo. o método compreende administrar uma quantidade eficaz de uma dicetopiperazina, uma pró-droga de uma dicetopiperazina ou um sal farmaceuticamente aceitável de qualquer uma das mesmas ao animal, em que a dicetopiperazina tem a fórmula apresentada no relatório descritivo. a invenção também oferece um método de modulação do citoesqueleto de uma célula endotelial em uma animal. o método compreende administrar uma quantidade eficaz de uma dicetopiperazina, uma pró-droga de uma dicetopiperazina ou um sal farmaceuticamente aceitável de qualquer uma das mesmas ao animal, em que a dicetopiperazina tem a fórmula apresentada no relatório descritivo. a invenção oferece ainda um kit. o kit compreende uma dicetopiperazina, uma pró-droga de uma dicetopiperazina ou um sal farmaceuticamente aceitável de qualquer uma das mesmas ao animal, em que a dicetopiperazina tem a fórmula apresentada no relatório descritivo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38040410P | 2010-09-07 | 2010-09-07 | |
| PCT/US2011/050612 WO2012033789A2 (en) | 2010-09-07 | 2011-09-07 | Treatment of diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112013005432A2 true BR112013005432A2 (pt) | 2016-06-07 |
| BR112013005432A8 BR112013005432A8 (pt) | 2017-12-05 |
Family
ID=45771136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013005432A BR112013005432A8 (pt) | 2010-09-07 | 2011-09-07 | tratamento de doenças |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20120058934A1 (pt) |
| EP (1) | EP2613795B1 (pt) |
| JP (2) | JP5941047B2 (pt) |
| KR (1) | KR101822951B1 (pt) |
| CN (1) | CN103200952B (pt) |
| AU (1) | AU2011299353B2 (pt) |
| BR (1) | BR112013005432A8 (pt) |
| CA (1) | CA2810834C (pt) |
| CO (1) | CO6710904A2 (pt) |
| EA (1) | EA023932B1 (pt) |
| ES (1) | ES2611878T3 (pt) |
| HK (1) | HK1182617A1 (pt) |
| IL (1) | IL224931A (pt) |
| MX (1) | MX343160B (pt) |
| NZ (1) | NZ607600A (pt) |
| SG (2) | SG10201507120TA (pt) |
| WO (1) | WO2012033789A2 (pt) |
| ZA (1) | ZA201301601B (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1311269B1 (en) | 2000-08-04 | 2012-02-29 | DMI Biosciences, Inc. | Method of using diketopiperazines and composition containing them |
| ES2572975T3 (es) * | 2003-05-15 | 2016-06-03 | Ampio Pharmaceuticals, Inc. | Tratamiento de enfermedades mediadas por los linfocitos T |
| US8217047B2 (en) | 2008-05-27 | 2012-07-10 | Dmi Acquisition Corp. | Therapeutic methods and compounds |
| SG10201507120TA (en) * | 2010-09-07 | 2015-10-29 | Ampio Pharmaceuticals Inc | Treatment of diseases |
| JP2013537195A (ja) | 2010-09-07 | 2013-09-30 | ディエムアイ アクイジション コーポレイション | 疾患の治療 |
| CN103841987B (zh) | 2011-10-10 | 2015-06-17 | 安皮奥制药股份有限公司 | 退行性关节病的治疗 |
| MX2014003856A (es) | 2011-10-10 | 2015-01-16 | Ampio Pharmaceuticals Inc | Dispositivos medicos implantables con tolerancia inmune incrementada y metodos para hacerlos e implantarlos. |
| SG10201605205VA (en) | 2011-10-28 | 2016-08-30 | Ampio Pharmaceuticals Inc | Treatment of rhinitis |
| EP2968315B1 (en) | 2013-03-15 | 2020-06-03 | Ampio Pharmaceuticals, Inc. | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same |
| US20160106130A1 (en) | 2013-06-10 | 2016-04-21 | Suntory Holdings Limited | Plant extract containing diketopiperazine and method for producing same |
| CN103913853A (zh) * | 2013-07-05 | 2014-07-09 | 马准吾 | 具备冷感包覆层的隐形眼镜 |
| EP3183240A4 (en) | 2014-08-18 | 2018-06-27 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
| US11389512B2 (en) | 2015-06-22 | 2022-07-19 | Ampio Pharmaceuticals, Inc. | Use of low molecular weight fractions of human serum albumin in treating diseases |
| KR20180030915A (ko) | 2015-07-27 | 2018-03-26 | 산토리 홀딩스 가부시키가이샤 | 고리형 디펩티드 및 감미료를 함유하는 조성물 |
| KR102396603B1 (ko) | 2015-09-16 | 2022-05-11 | 원광대학교산학협력단 | 시트룰린을 유효성분으로 함유하는 간 기능 개선용 조성물 |
| CN105879005A (zh) * | 2016-02-01 | 2016-08-24 | 四川好医生攀西药业有限责任公司 | 一种治疗溃疡性结肠炎的药物组合物及其制备方法和应用 |
| CN109563150A (zh) * | 2016-07-26 | 2019-04-02 | 安皮奥制药股份有限公司 | 由血管高通透性介导的疾病的治疗 |
| CN111033637B (zh) | 2017-08-08 | 2023-12-05 | 费森尤斯医疗保健控股公司 | 用于治疗和评估慢性肾脏疾病的进程的系统和方法 |
| JP6741280B2 (ja) * | 2018-03-29 | 2020-08-19 | 株式会社ウォーターエージェンシー | Ａｃｅ阻害、血圧上昇抑制、又は血圧降下に用いられる組成物、及びその製造方法 |
| WO2021195265A1 (en) | 2020-03-24 | 2021-09-30 | Ampio Pharmaceuticals, Inc. | Methods for treating diseases associated with respiratory viruses |
| CN113754598B (zh) * | 2021-09-29 | 2023-06-06 | 四川大学 | 含环肽结构的二胺、聚酰亚胺及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000327575A (ja) * | 1999-05-26 | 2000-11-28 | Teika Seiyaku Kk | ジケトピペラジン誘導体含有炎症疾患治療剤および新規なジケトピペラジン誘導体 |
| EP1311269B1 (en) * | 2000-08-04 | 2012-02-29 | DMI Biosciences, Inc. | Method of using diketopiperazines and composition containing them |
| CN1791420A (zh) * | 2003-05-15 | 2006-06-21 | Dmi生物科学公司 | T－细胞介导的疾病的治疗 |
| ES2572975T3 (es) * | 2003-05-15 | 2016-06-03 | Ampio Pharmaceuticals, Inc. | Tratamiento de enfermedades mediadas por los linfocitos T |
| MX2010003113A (es) * | 2007-09-25 | 2010-04-01 | Abbott Lab | Compuestos de octahidropentaleno como antagonistas del receptor de quimiocina. |
| US8217047B2 (en) * | 2008-05-27 | 2012-07-10 | Dmi Acquisition Corp. | Therapeutic methods and compounds |
| SG10201507120TA (en) * | 2010-09-07 | 2015-10-29 | Ampio Pharmaceuticals Inc | Treatment of diseases |
| JP2013537195A (ja) * | 2010-09-07 | 2013-09-30 | ディエムアイ アクイジション コーポレイション | 疾患の治療 |
-
2011
- 2011-09-07 SG SG10201507120TA patent/SG10201507120TA/en unknown
- 2011-09-07 EA EA201390347A patent/EA023932B1/ru not_active IP Right Cessation
- 2011-09-07 SG SG2013015680A patent/SG187986A1/en unknown
- 2011-09-07 BR BR112013005432A patent/BR112013005432A8/pt not_active IP Right Cessation
- 2011-09-07 CN CN201180053553.8A patent/CN103200952B/zh active Active
- 2011-09-07 AU AU2011299353A patent/AU2011299353B2/en not_active Ceased
- 2011-09-07 CA CA2810834A patent/CA2810834C/en not_active Expired - Fee Related
- 2011-09-07 KR KR1020137008193A patent/KR101822951B1/ko active IP Right Grant
- 2011-09-07 ES ES11824038.1T patent/ES2611878T3/es active Active
- 2011-09-07 EP EP11824038.1A patent/EP2613795B1/en active Active
- 2011-09-07 JP JP2013528256A patent/JP5941047B2/ja not_active Expired - Fee Related
- 2011-09-07 NZ NZ607600A patent/NZ607600A/en not_active IP Right Cessation
- 2011-09-07 US US13/227,098 patent/US20120058934A1/en not_active Abandoned
- 2011-09-07 MX MX2013002566A patent/MX343160B/es active IP Right Grant
- 2011-09-07 WO PCT/US2011/050612 patent/WO2012033789A2/en active Application Filing
-
2013
- 2013-02-26 IL IL224931A patent/IL224931A/en active IP Right Grant
- 2013-03-01 ZA ZA2013/01601A patent/ZA201301601B/en unknown
- 2013-04-05 CO CO13089531A patent/CO6710904A2/es unknown
- 2013-08-23 HK HK13109875.6A patent/HK1182617A1/zh not_active IP Right Cessation
-
2016
- 2016-05-19 JP JP2016100487A patent/JP2016145261A/ja active Pending
-
2019
- 2019-09-25 US US16/582,953 patent/US20200016152A1/en not_active Abandoned
-
2020
- 2020-11-05 US US17/090,673 patent/US20210052578A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2613795A2 (en) | 2013-07-17 |
| ZA201301601B (en) | 2018-12-19 |
| JP5941047B2 (ja) | 2016-06-29 |
| BR112013005432A8 (pt) | 2017-12-05 |
| MX343160B (es) | 2016-10-26 |
| CA2810834C (en) | 2017-03-21 |
| NZ607600A (en) | 2015-05-29 |
| EP2613795A4 (en) | 2013-10-30 |
| ES2611878T3 (es) | 2017-05-11 |
| AU2011299353A1 (en) | 2013-03-14 |
| IL224931A (en) | 2017-05-29 |
| EA201390347A1 (ru) | 2013-07-30 |
| WO2012033789A2 (en) | 2012-03-15 |
| JP2013537194A (ja) | 2013-09-30 |
| CO6710904A2 (es) | 2013-07-15 |
| JP2016145261A (ja) | 2016-08-12 |
| SG10201507120TA (en) | 2015-10-29 |
| HK1182617A1 (zh) | 2013-12-06 |
| CA2810834A1 (en) | 2012-03-15 |
| US20210052578A1 (en) | 2021-02-25 |
| CN103200952A (zh) | 2013-07-10 |
| KR20140003399A (ko) | 2014-01-09 |
| WO2012033789A3 (en) | 2012-05-31 |
| US20120058934A1 (en) | 2012-03-08 |
| EP2613795B1 (en) | 2016-10-26 |
| EA023932B1 (ru) | 2016-07-29 |
| SG187986A1 (en) | 2013-03-28 |
| KR101822951B1 (ko) | 2018-01-29 |
| CN103200952B (zh) | 2016-04-06 |
| US20200016152A1 (en) | 2020-01-16 |
| AU2011299353B2 (en) | 2016-02-25 |
| MX2013002566A (es) | 2013-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013005432A8 (pt) | tratamento de doenças | |
| BR112014031204A2 (pt) | derivados deuterados de ruxolitinib | |
| BR112015023412A8 (pt) | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso. | |
| MX2016001587A (es) | Inhibidores de kdm1a para el tratamiento de enfermedades. | |
| BR112013010310A2 (pt) | inibidores de acetil-coa carboxilase de lactama n1/n2 | |
| BR112014026703A2 (pt) | inibidores de dna-pk | |
| BR112012011072A2 (pt) | inibidores de n1-pirazolospirocetona acetil-coa carboxilase | |
| BR112015011497A2 (pt) | composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença | |
| EA201201648A1 (ru) | Стимуляторы sgc | |
| MX2011011335A (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina. | |
| BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112012009215A2 (pt) | "terapia combinada contra o cancer com compostos inibidores de hsp90" | |
| MX2011009796A (es) | Inhibidores de la cinasa pi3. | |
| MX2011013034A (es) | 1-(piperidin-4-yl)-pirazol derivados como moduladores de gpr 119. | |
| BR112012008518A2 (pt) | derivado heterocíclico, e, composição farmacêutica | |
| BR112012031580A2 (pt) | derivado de tetra-hidrocarbolina | |
| BR112016029781A2 (pt) | composições e métodos para inibir a expressão de gene de alfa-1 antitripsina | |
| EA201391485A1 (ru) | Способы и композиции для лечения нейродегенеративных заболеваний | |
| UA112055C2 (uk) | Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну | |
| BR112013006344A2 (pt) | lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas | |
| BR112013007343A2 (pt) | métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica | |
| BR112012028857A2 (pt) | formulações farmacêuticas que compreendem derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenzeno como inibidores de sglt | |
| BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical | |
| BR112015003729A2 (pt) | composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente | |
| MY167898A (en) | Co-crystals and salts of ccr3-inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: AMPIO PHARMACEUTICALS. INC. (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2530 DE 02-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |